Clinical Trials Directory

Trials / Unknown

UnknownNCT03941314

A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease

A Prospective Randomized, Parallel-group, Multicentre, Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
300 (actual)
Sponsor
Kantonsspital Winterthur KSW · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study (superiority trial) is to compare the Supera® Peripheral Stent System with a standard nitinol self-expanding stent for treatment of femoro-popliteal arterial occlusive disease. Hypothesis: The Supera® stent is superior to a standard nitinol self-expanding stent, for treatment of femoro-popliteal artery disease in terms of (1) primary patency rate and (2) need for revascularization up to 24 months after stent insertion.

Conditions

Interventions

TypeNameDescription
DEVICESupera® Peripheral Stent SystemThe index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
DEVICEEverFlex™ Self-Expanding Peripheral Stent SystemThe index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.

Timeline

Start date
2019-06-25
Primary completion
2026-03-01
Completion
2026-03-01
First posted
2019-05-07
Last updated
2024-03-29

Locations

3 sites across 2 countries: Spain, Switzerland

Source: ClinicalTrials.gov record NCT03941314. Inclusion in this directory is not an endorsement.